In seeking a data-driven approach to efficient drug development, MMS aims to enhance its capabilities in advanced clinical trial design, innovative statistics, and data science with the acquisition.

In this exclusive Drug Digest video interview Anil Kane from Thermo Fisher Scientific will be tackling the topic of advances in small-molecule manufacturing and several other experts will provide brief commentaries on associated topics.

This site was previously the beneficiary of a €7.3 million (US$7.6 million) investment, made in 2022, earmarked for the production of HPAPIs to treat cancer.

With the approval, FDA granted SpringWorks a rare pediatric disease priority review voucher.

Investing in STEM programs for girls in an education setting and then supporting women as they excel in their professional careers is key to ensuring that vital highly skilled personnel are not left behind.

Acoramidis was approved by FDA in November 2024 and is prescribed in the US under the brand name Attruby.

Pharmaceutical Technology® sat down with Jean Redmond, Chief Operating Officer at Biologit, to discuss the use of artificial intelligence in pharmaceutical research and development and the role women play in this fast-developing area.

The company says it is the pharmaceutical market’s first wet granulator with an integrated, truly continuous dryer.

While this approval addresses breast cancer, olaparib in combination with durvalumab was approved by the EU in August 2024 for treatment of endometrial cancer.

In a lead up to The International Day of Women and Girls in Science, Pharmaceutical Technology® takes a look at the unique perspective women bring to the use of artificial intelligence in the pharmaceutical industry.

These infections can be caused by certain Gram-negative microorganisms, making the infections challenging to control due to high antimicrobial resistance.

Experts provide their insights into the trends that have shaped the global bio/pharma industry in 2024 and give their predictions as to what may be impactful in 2025 and beyond.

Pharmaceutical Technology® sat down with Michelle Bridenbaker, COO of Unbiased Science, ahead of International Day of Women and Girls in Science to talk about the role of women in the pharmaceutical industry.

Pharmaceutical Technology® sat down with Kate Coleman from Arriello to run through the major trends from 2024, including the importance of technological advances, and how these may progress in 2025.

European biopharma companies are looking beyond GLP-1s.

Installation was performed during the summer of 2024, and the system has already successfully completed its first production run for a leading biotech company.

Patient enrollment is currently underway for the highest-dose cohort of AdvanCell’s potentially best-in-class targeted alpha therapy for metastatic prostate cancer.

In this interview, Pharmaceutical Technology® discusses the trend of AI in pharma and how it may play out in 2025 and beyond with Ben Sidders from Biorelate.

A new bioanalytical lab being opened by Ardena at the site is expected to be operational by the third quarter of 2025.

Hood, a pioneer of systems biology and systems medicine, shared his personal interest in starting a new peptide-based, informational-driven pharmaceutical company that would address wellness and longevity.

The transaction is expected to enhance Jabil’s development and commercial production of auto-injectors, pen injectors, inhalers, and on-body pumps.

The tariffs President Trump wants to levy against Canada and Mexico are on hold, for now, but China has already announced it intends to proceed with retaliatory tariffs against the US.

While FMS has specialized in the design, installation, and maintenance of environmental monitoring systems, Trescal’s focus has been on calibration and metrology services.

The company is recalling one lot of Fentanyl Transdermal System 25 mcg/h transdermal patches because of possible multi-stacking of patches.

Bio/pharma companies have a lot to consider when tackling social media communications, especially within Europe.

Another eight medications already authorized in the EU were recommended for extensions of various indications.

If the conditions prove optimal, 2025 could be a prosperous year for bio/pharma business deals.

AI regulations in healthcare are rapidly evolving, and one should consult with regulatory subject matter experts, says Siegfried Schmitt, PhD, vice president, Technical at Parexel.